It was nice to see the once a day dosing ability and a lowering of the male dosing concerns. Add in the better efficacy numbers and this drug should bury Xeljanz.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.